Last reviewed · How we verify
Placebo of SPM 962
Placebos do not have an active pharmacological mechanism; they are used as controls in clinical trials.
At a glance
| Generic name | Placebo of SPM 962 |
|---|---|
| Sponsor | Otsuka Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebos are designed to appear identical to the active drug being tested but contain no active ingredients. They help researchers determine the true effect of the active drug by comparing outcomes against a baseline.
Approved indications
Common side effects
Key clinical trials
- Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa (PHASE3)
- Study of SPM 962 in Patients With Restless Legs Syndrome (RLS) (PHASE3)
- A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients (PHASE3)
- A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients (PHASE2, PHASE3)
- A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of SPM 962 CI brief — competitive landscape report
- Placebo of SPM 962 updates RSS · CI watch RSS
- Otsuka Pharmaceutical Co., Ltd. portfolio CI